The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.

Theranostics · 2020 · PMC6956821 · PMID 31938054

Europe PMC DOI

hedged sentence

0.1070

closest p · 2.1× alpha

0.1070

boldest claim

The sentences

did not reach statistical significancep = 0.107not close (p > 0.1)

Over-expression of EGFR was indicative of a longer overall survival (OS) for M0 patients (p = 0.00209) whereas an inversion of this trend was observed for M1 patients although it did not reach statistical significance (p = 0.107, Figure S6 B-C ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.